Latest Breaking News On - குறிப்பிடத்தக்க வளர்ச்சி - Page 16 : comparemela.com

Share: ResearchAndMarkets.com s offering. Based on epidemiological analysis, the number of diagnosed prevalent cases of T2D will grow by 28.76% over the forecast period, at an AGR of 2.3%, from 164,826,095 cases in 2018 to 216,029,212 cases by 2029 across the nine major pharmaceutical markets covered in this report, the US, 5EU (France, Germany, Italy, Spain and UK), Japan, India and China. The report projects that the marketplace for T2D within the 9MM will grow from $48bn in 2019 at a compound annual growth rate (CAGR) of 6.7% to $91.9B by 2029. In particular, the report expects the US market will contribute the most to the antidiabetic market s growth, contributing sales in $28B sales in 2019 (58% of the global antidiabetic market) and $57B in 2029 (62% of the global antidiabetic market).

United kingdomOramed pharamceuticalsEli lillyLaura woodBoehringer ingelheimMerck coHua medicine shanghai ltdBiocon ltdSihuan pharmaceutical holdings group ltdJiangsu hengrui medicine coCustom researchD developers battle for shareLexicon pharmaceuticalsOffice hours callCompany profilesE st office hours call